Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now

Q2 Preview | Sun Pharma consolidated net may drop 4% on high R&D costs

Sun Pharmaceutical’s consolidated revenues, however, are expected to rise 13.2 percent on a year-on-year basis aided by growth in US specialty products and domestic formulations portfolio

Mumbai / October 31, 2022 / 01:32 PM IST
Sun Pharma

Sun Pharma

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Sun Pharmaceutical Industries is likely to report muted operating performance and earnings with 4 percent decline in the on-year consolidated net profit for the quarter ended September 2022.

A Moneycontrol poll of six brokerage houses has pegged the consolidated post-tax profit for the country's largest pharmaceutical company by sales volume at Rs 1,968.4 crore. The company will report its September quarter earnings on November 1.

The decline in bottomline performance may have been caused by a tepid operating performance in the reporting quarter with growth in consolidated operating profit for the quarter estimated at a mere 0.5 percent on-year to Rs 2,719.9 crore.

Sun Pharma 3110_001